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OBJECTIVES: To evaluate effects of dose escalation on clinical outcomes of RA
patients initiating TNF-blocker treatments in community practice. METHODS:
TNF-blocker-naïve adult RA patients initiating etanercept, adalimumab, or inflix-
imab (index) between July 1, 2005 and May 31, 2008 with 12 months’ enrollment
post-index were identified from the Ingenix database. Patients receiving 9
months TNF-blocker treatment or diagnosed with psoriasis, psoriatic arthritis, an-
kylosing spondylitis, or Crohn’s disease were excluded. Rates of dose escalation
using 3 different methods were calculated using claims data. Participating physi-
cians provided de-identified charts. Each chart was reviewed by 4–6 clinical rheu-
matologists to evaluate and agree on overall clinical change from baseline to the
visit closest to 1 year post-index (123 months). Multivariate models compared
change in clinical outcomes and dose escalation rates, controlling for differences
among etanercept, adalimumab, and infliximab patients at index. RESULTS: Over-
all, 715 etanercept, 501 adalimumab, and 393 infliximab patients were identified
from claims; 141 etanercept, 115 adalimumab, and 104 infliximab patients had
evaluable charts. Patient characteristicswere similar among the claims and charts.
Regardless of dose escalation method used, significantly fewer etanercept-treated
patients had dose escalations (1.8%, 5.2%, 6.7%) than patients treated with adali-
mumab (9.8%, 8.6%, 10.4% respectively) or infliximab (50%, 31%, 34% respectively)
(p0.05 for all comparisons). After treatment initiation, 86% of etanercept-treated
patients had “much better” or “better” clinical outcomes at 123 months, versus
82% of adalimumab patients and 78% of infliximab patients. Multivariate analyses
showed significantly fewer dose escalations in etanercept patients (p0.05), with
no significant difference in clinical change score between etanercept patients and
adalimumab (p0.22) or infliximab (p0.07) patients. CONCLUSIONS: This study
showed dose escalation in fewer etanercept than adalimumab or infliximab patients,
but similar improvements in clinical outcomes for all 3 treatments, indicating that
higher dose escalation rates may not be associated with better clinical outcomes.
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OBJECTIVES: Using linked administrative databases from Ontario, our study exam-
ined the “realworld” cost, effectivenessandcost-effectivenessofRituximab indiffuse-
large-B-cell lymphoma.METHODS: Patientswere defined as thosewhohad a diagno-
sis of diffuse-large-B-cell lymphoma according to ICD-O histology classification
between January 1997 and December 2007 and received either CHOP (cyclophospha-
mide, doxorubicin, vincristine and prednisone) or R-CHOP (CHOP plus Rituximab) as
first line treatment.Weusedahistorical cohort design to compare theoverall survival,
toxicity profiles, direct costs, and cost-effectiveness of CHOP before Rituximab was
approved (pre-era CHOP) with R-CHOP after Rituximab approval (post-era RCHOP).
R-CHOP and CHOP patients were hard-matched on age, and then subsequently
matched on propensity scores by use of a 1:1 matching algorithm. Propensity scores
were calculated from demographic and clinical history information. We estimated
resourceuse anddirectmedical costs using the linkedadministrativedata. To analyze
censored cost data, we employed and compared different methods, including the
simple non-adjusted average, the Kaplan-Meier sample average estimator, inverse
probability weighting estimator, Pfeifer and Bang’s estimator (2005) and Basu’s two-
part estimator (2010). RESULTS: A total of 1131 matched pairs of patients were eval-
uated. 3-year overall survivalwas significantly improved in the post-era RCHOP group
compared to pre-era CHOP (69% [95%CI 66-71] vs 59% [95%CI 56-62]; Klein test
p0.001). Groups did not differ in the frequency of adverse events, but 3-year direct
cost was significantly higher in the post-era RCHOP group. The incremental cost-
effectiveness ratio varied depending on the method employed. CONCLUSIONS: This
study illustrated how different methods can be applied to observational data to esti-
mate costs and cost-effectiveness. The results from this study can be compared to
those from clinical trials and economic models. This will help drug decision-makers
calibrate healthcare policies while helping researchers evaluate assumptions made
andmethods used in economic models.
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OBJECTIVES: The project aimed to develop a secure, interactive tool to enable
researchers to perform comparative effectiveness studies and other types of re-
search on a multipayer claims database with reduced need for complicated
programming. METHODS: A common data model, through which multiple data
sources are standardized and linked via commondata structures and vocabularies,
was established. It was used to format five administrative databases: the Medicare
Chronic Condition Warehouse, the Thomson Reuters MarketScan® Medicaid Mul-
tistate, Medicare Supplemental, and Commercial databases, and the Healthcare
Cost and Utilization Project National Inpatient Sample database. A web-based Us-
er-Interface was developed that captures the logic typically required by CERmeth-
ods and capitalizes on the longitudinality of administrative data. Tools were de-
veloped to allow users to search taxonomies to select particular drugs, diagnoses,
or procedures by typing in substrings of the numeric codes or textual descriptions.
The tool allows researchers to apply enrollment and demographic constraints and
create variables. CER studies were conducted including a comparison of atrial fi-
brillation treatment with rate or rhythm control medications. RESULTS: The tool
allowed users to quickly define a study sample. Flow diagrams graphically illus-
trated the attrition of the sample size and visualization of treatment and outcomes.
Embedded SAS procedures enabled reporting and analysis of comparison popula-
tions. The analyses revealed a higher rate of coronary artery disease and heart
failure prior to drug initiation among the amiodorone versus the calcium channel
blocker population and a higher rate of post-drug initiation acquired hypothyroid-
ism, and pulmonary disease among the amiodorone versus the calcium channel
blocker population. CONCLUSIONS: New data designs and software analytic tools
may allow claims databases to bemore efficiently leveraged. The tool developed for
this project has the following advantages: 1) allows for a substantial portion of the
research exploration, hypothesis generation; and statistical analysis to be per-
formed in real-time using aweb-based interface; 2) improves the speed of research;
and 3) allows access to a multipayer database.
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OBJECTIVES: During the debate over health reform, comparative effectiveness re-
search was touted as a relatively painless approach to reducing costs. A compara-
tive effectiveness study of two treatments will find either that the costlier treat-
ment is more effective or is not more effective than a less expensive alternative.
Studies that report negative results have the potential to reduce costs, but only if
findings affect clinical practice. One concern is that the same factors that promote
rapid adoption of new therapies in the U.S. may retard the abandonment of exist-
ing technologies found to be ineffective.METHODS: The COURAGE trial found that
optimalmedical therapy is as effective as percutaneous coronary intervention (PCI)
for patients with stable angina. PCI refers to stenting and angioplasty. The trial was
published and widely publicized in early 2007. We evaluate trends in PCI volume
pre- and post-COURAGE by indication using 1) 100% samples of outpatient and
inpatient discharge data for California, Florida, New Jersey, andMaryland, 2) a 100%
sample of discharge data for Veteran’s Administration hospitals and 3) data from a
proprietary cardiac catheterization laboratory registry at 15 hospitals. RESULTS:
Between the fourth quarter of 2006 and the fourth quarter of 2007, PCI volume in
California, Florida, New Jersey, and Maryland among patients without serious cor-
onary disease declined from approximately 17,000 to 13,000 procedures (an 18%
decline). There was only a 5% decline among patients with unstable angina, who
were not included in COURAGE. We found similar patterns in the other datasets.
CONCLUSIONS: Publication of the COURAGE trial had an impact on PCI volume.
Many patients with stable angina continue to receive PCI. The results are consis-
tent with the view that as long as the health system is configured around proce-
dural-based medicine, the impact of trials which find that medical therapy is as
effective as invasive procedures will be modest.
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OBJECTIVES: In dialysis patients, bone and mineral (phosphorous, calcium) and
regulatory hormones (parathyroid hormone (PTH)) become dysregulated, increas-
ing risk of fractures, cardiac events and death. First line treatment is a low phos-
phorus diet and prescription phosphate binders.We examined the impact of a refill
management system (RMS) - which helps patients proactively manage their refills
using predictive algorithms and refill reminders for prescriptions - on serum phos-
phorus, calcium and PTH in patients prescribed phosphate binder monotherapy.
METHODS: Data from a large dialysis organization were used to identify dialysis
patients prescribed monotherapy phosphate binder between 1/1/2008-9/30/2010
with at least 6 months of follow-up. Patients enrolled in the RMS were 1:1 propen-
sity score matched to patients not enrolled utilizing age, race, gender, dialysis
vintage, body mass index, baseline laboratory values (albumin, calcium, Kt/V,
phosphorus, PTH, normalized protein catabolic rate), Charlson comorbidity score,
and other comorbid conditions commonly associated with ESRD. The matched
cohorts were compared on the percent meeting guideline ranges for phosphorus
(3.5-5.5 mg/dL), corrected calcium (8.4-9.5 mg/dL) and PTH (150-600 pg/mL). Values
were assessed over the 6-months following the first phosphate binder prescription.
Differences between groups were tested using chi-square for proportions.
RESULTS: 3,247 RMS patients met the inclusion criteria and were matched 1:1 to a
cohort of non-RMS patients. There were no significant differences between the
groups on any baseline variables. Patients enrolled in the RMS were more likely to
be in target range over the 6month period on all 3 measures: phosphorus (58.0% vs
55.1%); corrected calcium (74.3% vs. 69.1%) and PTH (80.5% vs. 77.2%), compared to
propensity matched controls. All differences were significant at the p0.05 level.
CONCLUSIONS: Results indicate that participation in a pharmacy RMS is associ-
ated better laboratory outcomes for dialysis patients.
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